The CD28 cytoplasmic tail contains several potential phosphorylation sites for the serine/threonine kinase protein kinase C (PKC) and/or proline-directed serine/threonine kinases, such as extracellular signal-regulated kinases. We demonstrate that ligation of CD28 by B7.1 results in strong serine/threonine phosphorylation of CD28. It is unlikely that ligation-stimulated phosphorylation of CD28 is mediated via activation of PKC, since it was not prevented by pre-treatment of Jurkat cells with inhibitors of PKC, and it was not mimicked by treatment with PKC activators such as PMA. Nevertheless, despite the lack of detectable effects of PMA treatment on CD28 phosphorylation, PMA did partially inhibit the association of CD28 with the putative signalling molecule phosphatidylinositol 3-kinase (PI 3-kinase) and the subsequent accumulation of PtdIns(3,4,5)P3. PI 3-kinase exhibits dual specificity as both a lipid kinase and a protein serine kinase, and site-specific mutagenesis of the Tyr173 residue in the CD28 cytoplasmic tail, which abolishes CD28 coupling to PI 3-kinase [Pages, Ragueneau, Rottapel, Truneh, Nunes, Imbert and Olive (1994) Nature (London) 369, 327–329], also prevents ligation-stimulated phosphorylation of CD28. However, the two PI 3-kinase inhibitors wortmannin and LY294002 had no effect on phosphorylation of CD28 after ligation by B7.1. This study therefore demonstrates that (1) a CD28-activated serine/threonine kinase distinct from both PKC and PI 3-kinase mediates ligation-stimulated CD28 phosphorylation, and (2) the PMA-stimulated down-regulation of the coupling of CD28 to PI 3-kinase is not due to PMA-stimulated phosphorylation of CD28.
Skip Nav Destination
Follow us on Twitter @Biochem_Journal
Article navigation
August 1997
-
Cover Image
Cover Image
- PDF Icon PDF LinkFront Matter
Research Article|
August 15 1997
Evidence that a kinase distinct from protein kinase C and phosphatidylinositol 3-kinase mediates ligation-dependent serine/threonine phosphorylation of the T-lymphocyte co-stimulatory molecule CD28
Richard V. PARRY;
Richard V. PARRY
*Pharmacology Group, School of Pharmacy and Pharmacology, Bath University, Claverton Down, Bath BA2 7AY, U.K.
Search for other works by this author on:
Daniel OLIVE;
Daniel OLIVE
‡INSERM U119, 27 Boulevard Lei Roure, Marseille 13009, France
Search for other works by this author on:
John WESTWICK;
John WESTWICK
*Pharmacology Group, School of Pharmacy and Pharmacology, Bath University, Claverton Down, Bath BA2 7AY, U.K.
Search for other works by this author on:
David M. SANSOM;
David M. SANSOM
†Bath Institute for Rheumatic Diseases, School of Pharmacy and Pharmacology, Bath University, Claverton Down, Bath BA2 7AY, U.K.
Search for other works by this author on:
Stephen G. WARD
Stephen G. WARD
1
*Pharmacology Group, School of Pharmacy and Pharmacology, Bath University, Claverton Down, Bath BA2 7AY, U.K.
1To whom correspondence should be addressed.
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
February 11 1997
Revision Received:
April 14 1997
Accepted:
April 23 1997
Online ISSN: 1470-8728
Print ISSN: 0264-6021
The Biochemical Society, London © 1997
1997
Biochem J (1997) 326 (1): 249–257.
Article history
Received:
February 11 1997
Revision Received:
April 14 1997
Accepted:
April 23 1997
Citation
Richard V. PARRY, Daniel OLIVE, John WESTWICK, David M. SANSOM, Stephen G. WARD; Evidence that a kinase distinct from protein kinase C and phosphatidylinositol 3-kinase mediates ligation-dependent serine/threonine phosphorylation of the T-lymphocyte co-stimulatory molecule CD28. Biochem J 15 August 1997; 326 (1): 249–257. doi: https://doi.org/10.1042/bj3260249
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Follow us on Twitter @Biochem_Journal
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() View past webinars > |